Global Blood Coagulation Analyzer Market, By Technology (Optical Technology, Mechanical Technology, Electrochemical Technology, Others), Test Type (APTT, D-Dimer, Fibrinogen, PT), End Use (Hospitals, Blood Bank, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
A blood coagulation analyzer is a device that detects clotting deficits associated with thrombocytopenia, thromboembolic disease, haemophilia, reduced liver function, von Willebrand disease, and other disorders by measuring the clotting mechanisms of hemostasis.
Data Bridge Market Research analyses that the blood coagulation analyzer market which was USD 4.2 billion in 2021, would rocket up to USD 8.59 billion by 2029, and is expected to undergo a CAGR of 9.35% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Technology (Optical Technology, Mechanical Technology, Electrochemical Technology, Others), Test Type (APTT, D-Dimer, Fibrinogen, PT), End Use (Hospitals, Blood Bank, Others)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Abbott (U.S), Danaher (U.S), Siemens (Germany), Sysmex Corporation (U.S), Thermo Fisher Scientific Inc. (U.S), Horiba Ltd. (Japan), Nihon Kohden Corporation (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Maccura Biotechnology Co. Ltd. (China), Bio Group Medical System (Italy), Genrui Biotech Co. Ltd. (China), A&T Corporation (Japan), Beijing Succeeder Technology Inc. (China), Diagnostica Stago SAS (France), Helena Laboratories Corporation (U.S), Hycel (Austria)
A blood coagulation analyzer is a device that determines blood clots. Hemophilia and thrombocytopenia are two clotting abnormalities that are detected and diagnosed with this test. In addition, this device is frequently used to assess blood platelet levels. Obesity, diabetes, blood clot-heart attack, and hypertension are only a few of the disorders that have resulted from lifestyle changes.
Blood Coagulation Analyzer Market Dynamics
- Rising incidence of cardiovascular diseases
Rising incidence of cardiovascular illnesses and blood disorders is likely to have a substantial impact on the blood coagulation analyzer market in the forecast period of 2022 to 2029. Another important factor driving the expanding use of blood coagulation analyzers is the growing senior population, rising healthcare costs, technological developments, and rising obesity rates. Emerging markets and the growing reagent rental business, on the other hand, will provide significant chances for the blood coagulation analyzer market to grow throughout the forecast period.
- New innovative technologies
The introduction of innovative analyzers by key market players that are tiny and simple to integrate has sparked a demand for such analyzers to be widely used in a variety of medical facilities. Furthermore, the increasing awareness of the health-care system in many parts of the world is increasing demand for such analyzers. The overall industry is also being propelled by rapid advancements and optimization in testing facilities.
- Demand for healthcare funds
Proliferation of innovative health care facilities, treatment centres, laboratory facilities, and academic institutions that have followed has resulted in a significant increase in demand for this type of analyzer. Demand for these analyzers is also increasing due to an increase in the number of heart attacks and blood diseases. Patients were able to utilise these analyzers at home to assess their coagulation state due to their convenience of use and performance features. The aforementioned factors are expected to enhance worldwide market growth.
In the last decade, rapid technological advancements and the launch of new coagulation analyzer tests have increased the quality and efficiency of hemostasis laboratories. Several current advanced coagulators have high throughput, adaptability, and reliability. Aside from that, they provide improved precision and accuracy, as well as easy-to-use complicated software with built-in graphs and calibration curves. In addition, the global prevalence of cardiac illnesses and blood disorders has risen dramatically, necessitating the development of improved coagulation analyzers.
High cost of fully mechanical coagulation analyzers will restrict the growth of blood coagulation analyzer market in the forecast period of 2022 to 2029. On the other hand, slow adoption of sophisticated hemostasis procedures in emerging and developing countries, are constraining market growth.
This blood coagulation analyzer market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the blood coagulation analyzer market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Blood Coagulation Analyzer Market
The sudden increasing cases of COVID-19 have caused increased consciousness of the population across the globe towards health. People are avoiding the products that do not come under essential commodities owing to the demand for these analyzers has been decreased. Moreover, the reduced supply chain affected the production and supply of the coagulation analyzer. Furthermore, due to disease severity and poor diagnosis of COVID-19 coagulation parameters are associated with it and is considered to be a risk factor for COVID-19.
- In April 2020, Enicor, a developer of blood coagulation diagnostic systems, was bought by Haemonetics Corporation, based in the United States.
- In October 2021, Trivitron Healthcare, a medical device firm, has introduced a new line of Diagon Ltd-manufactured Coagulation Analyzer products.
Global Blood Coagulation Analyzer Market Scope
The blood coagulation analyzer market is segmented on the basis of test type, technology and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Optical Technology
- Mechanical Technology
- Electrochemical Technology
- Blood Banks
Blood Coagulation Analyzer Market Regional Analysis/Insights
The blood coagulation analyzer market is analysed and market size insights and trends are provided by country, test type, technology and end-user as referenced above.
The countries covered in the blood coagulation analyzer market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the blood coagulation analyzer market due to the high favorable healthcare resources associated with increasing prevalence of cardio metabolic disorders.
Asia-pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the sufficient hospitals and clinics backed by trained healthcare staff equipped to give safe and effective healthcare.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Blood Coagulation Analyzer Market Share Analysis
The blood coagulation analyzer market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to blood coagulation analyzer market.
Some of the major players operating in the blood coagulation analyzer market are:
- Abbott (U.S)
- Danaher (U.S)
- Siemens (Germany)
- Sysmex Corporation (U.S)
- Thermo Fisher Scientific Inc. (U.S)
- Horiba Ltd. (Japan)
- Nihon Kohden Corporation (Japan)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Maccura Biotechnology Co. Ltd. (China)
- Bio Group Medical System (Italy)
- Genrui Biotech Co. Ltd. (China)
- A&T Corporation (Japan)
- Beijing Succeeder Technology Inc. (China)
- Diagnostica Stago SAS (France)
- Helena Laboratories Corporation (U.S)
- Hycel (Austria)